The antiplatelet effect of clopidogrel is not attenuated by statin treatment in patients with acute coronary syndromes undergone coronary stenting.
- Author:
Ya-ling HAN
1
;
Cheng-yang LI
;
Yi LI
;
Jian KANG
;
Cheng-hui YAN
Author Information
- Publication Type:Journal Article
- MeSH: Acute Coronary Syndrome; drug therapy; therapy; Aged; Angioplasty, Balloon, Coronary; Atorvastatin Calcium; Drug Interactions; Female; Heptanoic Acids; therapeutic use; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; therapeutic use; Male; Middle Aged; Platelet Aggregation; drug effects; Platelet Aggregation Inhibitors; therapeutic use; Pravastatin; therapeutic use; Prospective Studies; Pyrroles; therapeutic use; Ticlopidine; analogs & derivatives; therapeutic use
- From: Chinese Journal of Cardiology 2007;35(9):788-792
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo evaluate the interaction of atorvastatin or pravastatin with clopidogrel on platelet activation and aggregation function in patients with acute coronary syndromes (ACS) undergoing coronary stenting.
METHODSBetween April and December 2006, a total of 150 hospitalized ACS patients undergoing coronary stenting were randomized to receive atorvastatin (n = 50), pravastatin (n = 50) or no statin (n = 50) one day post procedure. All patients received standard antiplatelet treatment including aspirin 300 mg/d and loading dose 300 mg of clopidogrel followed by maintenance dose 75 mg/d. The expressions of CD62P and PAC-1 and the maximal platelet aggregation rate (MPAR) induced by 20 micromol/L ADP were measured at day 1 before statin therapy (baseline) and day 3 after procedure.
RESULTSBaseline clinical characteristics and levels of CD62P, PAC-1 and MPAR at the baseline were comparable among three groups. After 3-day statin treatment, the changes of CD62P [(4.69 +/- 16.78)% vs. (1.35 +/- 10.86)% vs. (2.97 +/- 10.21)%], PAC-1 [(12.78 +/- 22.07)% vs. (8.01 +/- 21.23)% vs. (10.65 +/- 21.39)%] and MPAR [(5.44 +/- 18.68)% vs. (7.15 +/- 19.59)% vs. (3.76 +/- 23.42)%] among three groups were not significantly different (all P > 0.05). Subgroup analysis showed that DeltaCD62P [(7.50 +/- 19.35)% vs. (3.24 +/- 11.18)% vs. (2.53 +/- 8.87)%], DeltaPAC-1 [(13.40 +/- 24.62)% vs. (11.28 +/- 19.90)% vs. (10.11 +/- 21.29)%] and DeltaMPAR [(7.56 +/- 19.11)% vs. (7.87 +/- 23.60)% vs. (6.75 +/- 23.30)%] in ACS patients were also similar among three groups (all P > 0.05).
CONCLUSIONNeither atorvastatin nor pravastatin attenuates the antiplatelet function of clopidogrel in ACS patients early post coronary stenting.
